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Abstract
Background: Colorectal cancer (CRC) is a major health problem in China and around the world. It is one of the
leading causes of cancer-related deaths. Research groups are thus searching for novel and more efficient anti-CRC
agents.
Results: Here we demonstrated that ABC294640, a novel SphK2 inhibitor, induced growth inhibition and apoptosis
in transformed and primary CRC cells. The SphK activity was remarkably inhibited by ABC294640, accompanied by
sphingosine-1-phosphate (S1P) depletion and ceramide incensement in CRC cells. Exogenously-added S1P inhibited
ABC294640-induced HT-29 cell lethality. While C6 ceramide and SphK1 inhibitor SKI-II facilitated ABC294640-induced
cytotoxicity against HT-29 cells. ABC294640 inhibited AKT-S6K1, but activated JNK signaling in transformed and
primary CRC cells. JNK inhibitors (SP600125 and JNKi-II) alleviated ABC294640-induced CRC cell apoptosis. Moreover,
a low concentration of ABC294640 sensitized the activity of 5-FU and cisplatin in vitro. In vivo, ABC294640 oral
administration dramatically inhibited HT-29 xenografts growth in nude mice.
Conclusions: Targeting of SphK2 by ABC294640 potently inhibits CRC cell growth both in vitro and in vivo,
ABC294640 could be developed as a novel therapeutic for the treatment of CRC.
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Background
Colorectal cancer (CRC) is a major health problem in
China and around the world [1, 2]. It is one of the lead-
ing causes of cancer-related deaths [1, 2]. Over the past
decades, significant improvements have been accom-
plished in chemotherapy treatments for CRC [1–3].
However, for those with advanced/malignant CRC, the
overall survival has not been remarkably prolonged [4].
Research groups are thus searching for novel and more
efficient anti-CRC agents [1, 2, 5–7].
Existing evidences have confirmed sphingosine kinase
(SphK) as an important therapeutic target for CRC and
other solid tumors [8]. SphK controls the balance of cel-
lular sphingolipids [9–11]. Activation of SphK leads to
generation of sphingosine-1-phosphate (S1P), which is a
known lipid signaling molecule promoting several pro-
cancer behaviors, including migration, differentiation,
survival, angiogenesis and immune cell modulation [12].
On the other hand, SphK inactivation will induce accu-
mulation of S1P precursors, including sphingosine and
ceramide, causing cell apoptosis and growth arrest [13].
Thus far, there are at least two isoforms of SphK,
SphK1 and SphK2, have been identified [14]. The onco-
genic role of SphK1 has been extensively studied in CRC
and other cancers [15]. Studies have demonstrated the
pivotal role of SphK1 in cellular proliferation, survival,
and its ability to reverse chemoresistance in CRC [15].
However, few is known about the role of SphK2 in CRC.
It has been shown that the ablation of SphK2 by RNA
interference (RNAi) inhibited cell proliferation and mi-
gration more effectively than that of SphK1 [16]. In CRC
cells, SphK2 siRNA downregulation facilitated sodium
butyrate-induced apoptosis [17].
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Recent studies have characterized a novel SphK2 inhibi-
tor, ABC294640, which was shown to suppress growth of
breast, kidney, and pancreatic cancer cells [18–20].
ABC294640 is a non-lipid competitive inhibitor of SphK2,
and exhibited chemotherapeutic pharmacological efficacy
in animal models without systemic toxicity [18–20]. How-
ever, the potential effect of ABC294640 in CRC, and the
underlying signaling mechanisms have been largely un-
known. In this study, we used ABC294640 as a pharmaco-
logical tool to determine the efficacy of targeting SphK2 as
a novel therapeutic intervention in the treatment of CRC.
Methods
Chemicals and antibodies
ABC294640 was purchased from DC Chemicals (Shanghai,
China). SKI-II (4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]-
phenol) was purchased from Tocris Bioscience (Ellisville,
Mo). Cell permeable short-chain C6 ceramide was ob-
tained from Avanti Polar Lipids, Inc. (Alabaster, AL). S1P
was purchased from Cayman Chemical Co. (Ann Arbor,
MI). 5-fluorouracil (5-FU) and cisplatin were purchased
from Sigma (Shanghai, China). SP600125 and JNK inhibi-
tor II (JNKi-II) were obtained from Selleck (Shanghai,
China). Antibodies against phospho (p)-AKT (Ser 473),
p-AKT (Thr 308), p-ribosomal protein S6 kinase 1
(S6K1) (Thr-389), p-JNK1/2 (Thr 183/Tyr 185) and
p-c-Jun (Ser73) were purchased form Cell Signaling Tech
(Denver MA). Anti-AKT1, SphK2, c-Jun and tubulin anti-
bodies were obtained from Santa Cruz (Santa Cruz, CA).
CRC cell lines and culture
CRC cell lines, including HT-29, HCT-116 and DLD-1,
were from the Cell Bank of CAS (Shanghai, China), cells
were cultured in RPMI/DMEM medium, with a 10 %
FBS in a CO2 incubator at 37 °C.
Primary colon cancer cell isolation and culture
Surgery-isolated colon cancer tissues were thoroughly
washed, non-cancerous surrounding tissues, if any, were
separated carefully under microscopy, and were dis-
carded. Clinical pathology reports confirmed those
tissues were indeed colon cancer tissues. Tissues were
then minced. The pellets were thoroughly washed, then
re-pelleted at 400 g for 5 min, and were subjected to
0.15 % (w/v) collagenase I digestion for 1 hour. Primary
cells were pelleted and rinsed twice with DMEM, cells
were then cultured in medium (DMEM, 15 % FBS,
10 mg/ml transferrin, 2 mM glutamine, 1 mM pyruvate,
10 mM HEPES, 100 units/ml penicillin/streptomycin,
0.1 mg/ml gentamicin, 0.2 units/ml insulin, 0.1 mg/ml
hydrocortisone, and 2 g/liter fungizone) [21]. Written in-
formed consents were obtained from all enrolled patients.
All clinical investigations were in accordance with princi-
ples expressed in the Declaration of Helsinki.
MTT assay of cell proliferation
CRC cell proliferation was analyzed by the 3-[4, 5-
dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium brom-
ide (MTT) assay. Briefly, 3,000 cells/well were plated in
96-well plates. After treatment, 20 μl/well of MTT (5 mg/
ml, Sigma) was added to culture medium for 2 hours. Ab-
sorbance was measured on a microplate reader (Bio-Rad,
Basel, Switzerland) at 570 nm.
Clonogenic survival assay
SKOV3 cells were plated in 6-well plates at 1000 cells
per well. Cells were then treated with gradient concen-
trations of ABC294640. Ten days after treatment, sur-
vival colonies were fixed with 3 % glutaraldehyde, 0.2 %
crystal violet and 20 % methanol, and were manually
counted.
Annexin V FACS assay of cell apoptosis
Apoptosis was detected by an Annexin-V-FITC apoptosis
detection kit (BD Pharmingen, San Diego, CA). Briefly,
CRC cells were harvested and washed twice (with PBS),
and then incubated for 15 min with Annexin-V-FITC and
propidium iodide (PI). Both early (Annexin V+/PI−) and
late (Annexin V+/PI+) apoptotic cells were sorted by the
fluorescence activated cell sorter (FACS) machine (Becton
Dickinson FACS Calibur, San Jose, CA). The percentage
of Annexin V stained cells was gated as a quantitative
measurement of cell apoptosis.
Fragmented DNA detection by ELISA
Nucleosomal DNA fragmentation is one of the biological
markers for apoptosis. Fragmented DNA was assessed by
measuring DNA-associated with nucleosomal histones
using a specific two-site ELISA with an anti-histone pri-
mary antibody and a secondary anti-DNA antibody, ac-
cording to the manufacturer's instructions (Roche Applied
Science, Shanghai, China). ELISA OD at 450 nm was re-
corded to measure cell apoptosis.
Lactate dehydrogenase (LDH) assay
LDH content released into conditional medium indicates
the level of toxicity. LDH content was assayed by a LDH
detection kit from Roche Applied Science (Shanghai,
China). % LDH release = LDH released in conditional
medium/(LDH released in conditional medium + LDH
in cell lysates)* 100 %.
Western blots
Thirty μg of proteins per sample were separated by 10 %
SDS-PAGE gel, and were transferred to polyvinylidene
difluoride (PVDF) membranes (Millipore, Bedford, MA).
After blocking with 10 % non-fat dry milk (in PBST) for
1 hour, membranes were incubated with designed anti-
bodies (in PBST) overnight at 4 °C, followed by incubation
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with secondary antibodies (in PBST) for 1–2 hours at
room temperature. The blots were visualized with en-
hanced chemiluminescence (ECL) kit (Pierce, Shanghai,
China). The intensity of each band was quantified through
ImageJ software after normalized to corresponding load-
ing control.
Assay of SphK activity and S1P content
After treatment, 20 μg of cell lysates were incubated
with 25 μmol/L D-erythrosphingosine dissolved in 0.1 %
Triton X-100, 2 mmol/L ATP, and [γ-32P] ATP for
30 minutes at 37 °C in a final volume of 200 μL. The re-
action was stopped by adding 20 μL of HCl (1 N),
followed by 800 μL of chloroform/methanol/HCl (100:
200:1, v/v). After vigorous vortex, phases were separated
by centrifugation. Radio-labeled S1P was separated by 60
thin-layer chromatography (TLC) on silica gel G60-
plates with chloroform/acetone/methanol/acetic acid/
water (10:4:3:2:1, v/v) as solvent, and phosphate incorp-
oration was visualized and quantified using a scintilla-
tion counter (LS-6500, Beckman, Shanghai, China) [22].
The sphingosine kinase activity was valued as pmol/
hour/g protein, and was expressed as percentage of the
control group.
Enzymatic measurement of ceramide
Cellular ceramide content in CRC cells was analyzed by
the protocol reported in [23], and was valued as fmol by
nmol of phospholipid. Its level in the treatment group
was expressed as the percentage change of the control
cells.
HT-29 tumor bearing nude mice
A nude mice HT-29 xenograft experiment was per-
formed to evaluate the in vivo activity of ABC294640.
Animal care and procedures were in accordance with
guidelines and regulations of the Institutional Animal
Care and Use Committee (IACUC). This study is ap-
proved by the ethics committee of authors’ institutions.
SKOV3 cells (2 × 106 per mice) were implanted subcuta-
neously in right flanks, and tumor volumes were calcu-
lated by use of the equation: (L ×W2)/2. When the
tumors reached around 100 mm3, mice were randomly
assigned to three groups. Treatment was then adminis-
tered every day thereafter, consisting of oral doses of 5
or 20 mg of ABC294640/kg body weight or vehicle
(0.375 % Polysorbate-80). Mice body weight and tumor
volume measurements were performed every week. On
week 6, tumors were excised, and weighted.
Statistics analysis
Experiments in this study were repeated at least three
times. Data were expressed as mean values ± standard
deviations (SD). Statistics were analyzed by ANOVA
followed by the Tukey’s multiple comparison (SPSS 18.0,
Chicago, CA); The level of significance was P < 0.05. Cell
doubling time was also calculated by SPSS software.
Results
ABC294640 induces growth inhibition and apoptosis in
human CRC cell lines
We first examined the potential effect of ABC294640 on
CRC cell growth. CRC cell lines, including HT-29, HCT-
116 and DLD-1, were treated with applied concentrations
of ABC294640, cell growth was tested by MTT assay. Re-
sults showed that ABC294640 dose-dependently inhibited
CRC cell growth (Fig. 1a). The effect of ABC294640 was
also time-dependent, and it took at least 48 hours for
ABC294640 to exert the anti-proliferative activity in HT-
29 cells (Fig. 1b). Meanwhile, ABC294640 treatment de-
creased the number of survival HT-29 colonies, further
confirming its growth-inhibitory and cytotoxic activities
(Fig. 1c). Next, we tested the role of ABC294640 on HT-
29 cell apoptosis. Results of Annexin V FACS assay
(Fig. 1d) and histone-DNA ELISA assay (Fig. 1e) demon-
strated that ABC294640 induced significant apoptosis in
HT-29 cells. Meanwhile, LDH content in conditional
medium of ABC294640-treated cells was also increased
(Fig. 1f). Similar apoptosis and LDH results were also
seen in two other CRC cell lines (HCT-116 and DLD-1)
(Data not shown). Together, these results show that
ABC294640 induces growth inhibition and apoptosis in
cultured CRC cells.
ABC294640 decreases SphK activity, causing S1P
depletion and ceramide accumulation in CRC cells
Next, we tested the SphK activity in ABC294640-
treated CRC cells. As shown in Fig. 2a, ABC294640
at tested concentrations remarkably inhibited SphK
activity in HT-29 cells. Further, SphK activity was also
decreased in ABC294640-treated HCT-116 cells and
DLD-1 cells (Fig. 2b). As a consequence, the S1P con-
tent was decreased by ABC294640 in HT-29 cells
(Fig. 2c), and the cellular ceramide level was in-
creased (Fig. 2d). Note that, the expression level of
SphK2 (tested by Western blots) was not affected by
above ABC294640 treatment (Data not shown). Sig-
nificantly, exogenously-added S1P alleviated ABC294640-
induced growth inhibition and apoptosis in HT-29 cells
(Fig. 2e and f). Conversely, a short-chain ceramide (C6)
and the SphK1 inhibitor SKI-II exacerbated ABC294640-
induced HT-29 cytotoxicity (Fig. 2e and f). Ceramide (C6)
or the SKI-II alone also induced obvious cytotoxicity in
HT-29 cells (Fig. 2e and f). These results indicate that
ABC294640-induced anti-CRC activity in vitro is accom-
panied with SphK inactivation, S1P depletion and cer-
amide accumulation.
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ABC294640 was cytotoxic to primary human CRC cells
The activity of ABC294640 on patient-derived primary
cancer cells was tested. We successfully cultured primary
cancer cells from 3 different colon cancer patients. Their
corresponding in vitro growth curve and doubling time
were presented in Additional file 1: Figure S1A and B.
As shown in Fig. 3a, these primary cancer cells showed
differential expression of SphK2 expression. Patient-2-
derived cancer cells had highest level of SphK2, these
cells were extremely sensitive to ABC294640-induced
growth inhibition (Fig. 3b) and cell death (Fig. 3c). On
the other hand, patient-1-derived cancer cells had lowest
SphK2 level (Fig. 3a), the cytotoxic effect of ABC29464
was also relatively weak in those cells (Fig. 3b and c).
Thus, ABC294640 is cytotoxic to the tested primary can-
cer cells, and its activity is negatively associated with
SphK2 expression level. The morphology of these primary
cancer cells before and after ABC294640 treatment was
shown in Additional file 1: Figure S1C.
ABC294640 inactivates AKT-S6K1, but activates JNK
signaling in cultured CRC cells
Activation of AKT-mammalian target of rapamycin
(mTOR) signaling has been linked to CRC cell survival,
proliferation and chemo-resistance [24]. Next, we tested
the effect of ABC294640 on AKT-mTOR activation in
CRC cells. Activation of AKT was evidence by phosphory-
lated (p-) AKT at both Ser-473 and Thr-308. Western blot
results in Fig. 4a showed that ABC294640 at 1 μM or
3 μM remarkably inhibited AKT phosphorylation at both
sites in HT-29 cells. S6K1 phosphorylation, an indicator
of mTOR complex C1 (mTORC1) activation, was also
dramatically inhibited by ABC294640 (Fig. 4a). Expres-
sion of regular AKT and S6K1 was not affected by the
same ABC294640 treatment (Fig. 4a). Similar results
were also achieved in primary CRC cells (Fig. 4b).
Meanwhile, activation of JNK, tested by p-JNK1/2 and
p-c-Jun, was induced by same ABC294640 treatment in
HT-29 cells (Fig. 4c), and in primary CRC cells (Fig. 4d).
Notably, the JNK inhibitors, SP600125 and JNKi-II,
suppressed ABC294640-induced HT-29 growth inhib-
ition (Fig. 4e) and apoptosis (Fig. 4f ), indicating a pro-
apoptotic role of JNK activation by ABC294640 in CRC
cells. Similar results were also seen in primary cancer
cells (Data not shown).
ABC294640 sensitizes the activity of 5-FU and cisplatin
Chemoresistance is major problem in current CRC treat-
ment [1, 2]. The results above showed that ABC294640

















































































































































Fig. 1 ABC294640 induces growth inhibition and apoptosis in CRC cell lines. The relative growth (vs. Control group) of tested CRC cells with
indicated ABC294640 treatment was tested by MTT assay (a and b). HT-29 cells, treated with or without applied ABC294640 for indicated time,
were subjected to clonogenicity assay (c), Annexin V FACS assay (d), histone-DNA ELISA assay (e) or LDH release assay (f). Mean values ± SD of
three independent experiments were reported. Statistical analysis was performed comparing treatment groups with vehicle control group
(“C”). *P < 0.05
Xun et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:94 Page 4 of 9
S1P depletion, and ceramide accumulation in CRC cells.
All these should favor a chemo-sensitization conse-
quence [1, 2]. Thus, we tested the potential effect of
ABC294640 on 5-fluorouracil (5-FU) and cisplatin, two
widely utilized anti-CRC chemo-drugs, in CRC cells [1, 2].
As shown in Fig. 5a, 5-FU or cisplatin alone at tested con-
centration only induced moderate growth inhibition in
HT-29 cells, co-administration with a low concentration
of ABC294640 (0.3 μM) dramatically enhanced their sen-
sitivities (Fig. 5a). Meanwhile, LDH results showed that
ABC294640 remarkably facilitated 5-FU and cisplatin-
induced HT-29 cell death (Fig. 5b). Note that similar
chemo-sensitization effect by ABC294640 was also repro-
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Fig. 3 The cytotoxic effect of ABC294640 in primary human CRC cells. Ex vivo cultured primary cancer cells derived from three different colon
cancer patients (−1, male, 47 yeas old; −2, female, 62 years old; −3, male, 55 years old) were treated with or without ABC294640 (1 μM) for
72 hours, cell growth and cell death were tested by MTT assay (b) and LDH release assay (c), respectively. Expression of SphK2 and tubulin in
above cells was also shown (a). Mean values ± SD of three independent experiments were reported. Statistical analysis was performed comparing






















































































































































Fig. 2 The effect of ABC294640 on SphK activity, S1P or ceramide content in CRC cells. The relative SphK activity (a and b), S1P content (c) or
ceramide level (d) (vs. Control group) with indicated ABC294640 treatment were presented. The effect of S1P (5 μM), C6 ceramide (C6, 5 μM) or
SKI-II (5 μM) on ABC294640 (1 μM)-induced HT-29 cell growth inhibition and cell death were tested by MTT assay (e) and LDH release assay (f),
respectively. Mean values ± SD of three independent experiments were reported. Statistical analysis was performed comparing treatment groups
with vehicle control group (“C”). *P < 0.05. #P < 0.05 vs. ABC294640 only group (e and f)
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(Data not shown). These results demonstrate the 5-FU/
cisplatin sensitization effect by ABC294640 in cultured
CRC cells.
Oral administration of ABC294640 inhibits HT-29
xenografts growth in nude mice
At last, we studied the anti-CRC activity of ABC294640
in vivo. HT-29 tumor bearing nude mice model was ap-
plied. Established, sized-matched HT-29 tumors were di-
vided into three groups: low-dose ABC294640 (5 mg/kg,
daily, p.o.) treatment group (n = 10), high-dose ABC294640
(20 mg/kg, daily, p.o.) treatment group (n = 10), and the
vehicle (0.375 % Polysorbate-80) control group (n = 10).
Tumor growth curve results in Fig. 6a showed that oral ad-
ministration of ABC294640 (5 or 20 mg/kg) dramatically
inhibited HT-29 xenograft growth in nude mice. The
weights ABC294640-treated tumors were remarkably
lower than that of vehicle-treated group (Fig. 6b). Mice
body weights were not affected by ABC294640 administra-
tion throughout the experiment duration (see the data of
week-6 in Fig. 6c). Nor did we noticed any signs of system
toxicity or wasting. Thus, in line with the in vitro results,
oral administration of ABC294640 dramatically inhibits

















































































Fig. 4 Signaling changes in ABC294640-treated CRC cells. HT-29 cells or primary CRC cells were treated with or without ABC294640 (1/3 μM) for 12 hours,
listed proteins were tested by Western blots (a-d). HT-29 cells were pre-treated with SP600125 (5 μM) or JNK inhibitor II (JNKi-II, 5 μM) for 1 hour, followed
by ABC294640 (1 μM) stimulation, cell growth (e) and cell apoptosis (f) were analyzed. Mean values ± SD of three independent experiments were reported.











































Fig. 5 The in vitro chemo-sensitization activity by ABC294640. HT-29 cells were treated with 5-FU (5 μM), cisplatin (5 μM), or together with
ABC294640 (0.3 μM) for 72 hours, cell growth was tested by MTT assay (a), and cell death was evaluated by LDH release assay (b). Mean
values ± SD of three independent experiments were reported. Statistical analysis was performed comparing groups with or without ABC294640
co-treatment. *P < 0.05
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Discussions
SphK has been recognized as an important therapeutic
target in various solid tumors, mainly due to its roles in
cell proliferation, survival, apoptosis, differentiation, and
cell senescence [8, 14, 25, 26]. Thus far, at least two iso-
forms of SphK have identified, including SphK1 and
SphK2 [14]. The two have various tissue expression, and
subcellular localization [25, 27]. It has been shown that
SphK1 expression is highest in lung, spleen, kidney, and
blood; Meanwhile, overexpression of SphK2 is found in
liver, kidney, brain, and heart [28, 29]. In the current
study, we showed that SphK2 expression level was in-
consistent in different primary colon cancer cells, which
negatively correlated to ABC294640’s sensitivity. Al-
though the role of SphK1 in cancer progression has been
extensively studied in the literature [26], the function of
SphK2 on cell survival, growth and drug resistance has
only recently been elucidated [30, 31].
In the current study, our results showed that ABC294640,
the novel, specific and competitive SphK2 inhibitor, sup-
pressed SphK activation in CRC cells, causing S1P depletion
and ceramide accumulation. ABC294640 inhibited CRC cell
growth, and induced CRC cell apoptosis. Further, it sensi-
tized 5-FU- and cisplatin-mediated anti-HT-29 cell activity.
In vivo, oral administration of ABC294640 remarkably
inhibited HT-29 xenografts growth in nude mice, without
inducing system toxicity. These preclinical results suggest
that ABC294640might be an efficient anti-CRC agent.
One of the novel findings of this study is that
ABC294640 significantly inhibited AKT-mTOR (S6K1)
activation in both transformed and primary CRC cells.
Existing evidence have confirmed the pivotal role of
AKT-mTOR signaling in regulating CRC cancer cell
growth, proliferation, migration and survival. This path-
way is frequently dysregulated in CRC [24, 32, 33]. Thus,
AKT-mTOR inhibition by ABC294640 might be respon-
sible, at least in part, for its cytotoxic effects against CRC
cells. These results are not surprising, since SphK2
blockage by ABC294640 caused ceramide accumulation in
CRC cells. Ceramide is able to activate phosphatase 1A
(PP1A) or PP2 to directly de-phosphorylate AKT [34, 35].
S1P was shown to activate AKT through different mecha-
nisms [36], and decreased S1P in ABC294640-treated cells
might also be the reason of AKT-mTOR inactivation. The
detailed signaling mechanisms of AKT-mTOR inhibition
by this SphK2 inhibitor require further characterizations.
Another important signaling discovery of this study is
JNK activation by ABC294640 in tested CRC cells,
which is also involved in ABC294640-mediated activity.
Inhibition of JNK by two different JNK inhibitors allevi-
ated growth inhibition and apoptosis by ABC294640. Al-
though the detailed signaling mechanisms need further
investigation, there are possible speculations to explain
JNK activation by ABC294640. Chen et al., showed that
ceramide alone induced JNK activation and subsequent
cell apoptosis through thioredoxin-interacting protein-
mediated pathway [37]. SiRNA-mediated silencing of
JNK largely reversed ceramide-induced apoptosis [37].
Based on these information, it is possible that blockage
of SphK2 by ABC294640 leads to ceramide accumula-
tion, which actives JNK signaling to promote CRC cell
apoptosis.
One advantage of using of ABC294640, other than it is
a novel, highly-efficient and competitive SphK2 inhibitor,
is its oral availability. In the current study, our results
demonstrated that oral administration of a single dose of
ABC294640 (5 or 20 mg/kg, daily) dramatically inhibited
HT-29 xenograft growth in nude mice, leading to re-
markable tumor recession. That’s being said, however,
certain off-target effects of ABC294640 should be con-
sidered. For example, it has been previously shown that
ABC294640 binds to the E2 estrogen receptor (ER) in an
antagonistic manner, and similar to tamoxifen, this novel
SphK2 inhibitor represses ER signaling in both cellular
and animal models [31]. Although this is somehow ad-
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Fig. 6 ABC294640 inhibits HT-29 cell growth in vivo. The volumes of HT-29 xenograft tumors in nude mice administrated with ABC294640 (ABC, 5
or 20 mg/kg, p.o., daily) or vehicle (0.375 % Polysorbate-80) control were recorded weekly (n = 10 for each group) (a). Tumor weights (b) and mice
body weights (c) at week-6 were also presented. Statistical analysis was performed comparing treatment groups with vehicle control
group. *P < 0.05
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ER inhibition and other potential side effects should be
considered fully when given to human, and close moni-
toring of patients is thus recommended.
Conclusions
Thus, targeting of SphK2 by ABC294640 potently in-
hibits CRC cell growth both in vitro and in vivo,
ABC294640 could be developed as a novel therapeutic
for the treatment of CRC.
Additional file
Additional file 1: Figure S1. Same amount (1*103/dish) of the primary
colon cancer cells were cultured in FBS-containing medium for applied
time, number of viable cells (trypan blue exclusive) at each time point
was presented (A), their doubling-time was calculated, and was
compared to that of HT-29 cells (B). Above primary cancer cells were
treated with or without ABC294640 (1 μM) for 72 hours, representative
morphology images were shown (C). Mean values ± SD of three
independent experiments were reported. Magnification: 1: 200 (C).
(EPS 4507 kb)
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